X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (21890) 21890
Publication (1314) 1314
Book Review (386) 386
Magazine Article (313) 313
Book / eBook (311) 311
Book Chapter (150) 150
Newsletter (59) 59
Newspaper Article (34) 34
Conference Proceeding (15) 15
Dissertation (14) 14
Trade Publication Article (7) 7
Data Set (6) 6
Web Resource (6) 6
Paper (4) 4
Patent (4) 4
Government Document (2) 2
Journal / eJournal (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15114) 15114
index medicus (9795) 9795
administration, oral (8140) 8140
female (7858) 7858
male (7521) 7521
warfarin (5248) 5248
anticoagulants - administration & dosage (4960) 4960
aged (4957) 4957
middle aged (4936) 4936
anticoagulants (4714) 4714
anticoagulants - therapeutic use (4538) 4538
adult (3943) 3943
atrial fibrillation (3584) 3584
risk factors (3495) 3495
anticoagulants - adverse effects (3387) 3387
hematology (3292) 3292
peripheral vascular disease (2911) 2911
stroke (2713) 2713
cardiac & cardiovascular systems (2685) 2685
treatment outcome (2667) 2667
oral anticoagulants (2613) 2613
pharmacology & pharmacy (2503) 2503
dabigatran (2433) 2433
rivaroxaban (2282) 2282
aged, 80 and over (2220) 2220
animals (2175) 2175
venous thromboembolism (2149) 2149
thromboembolism (2143) 2143
risk (2097) 2097
atrial fibrillation - drug therapy (2086) 2086
prevention (2057) 2057
therapy (2035) 2035
management (2008) 2008
oral anticoagulation (1892) 1892
hemorrhage - chemically induced (1875) 1875
medicine, general & internal (1847) 1847
atrial-fibrillation (1774) 1774
surgery (1761) 1761
international normalized ratio (1696) 1696
stroke - prevention & control (1696) 1696
thrombosis (1650) 1650
analysis (1588) 1588
atrial fibrillation - complications (1567) 1567
dentistry, oral surgery & medicine (1515) 1515
time factors (1506) 1506
anticoagulation (1504) 1504
warfarin - therapeutic use (1502) 1502
care and treatment (1482) 1482
warfarin - administration & dosage (1446) 1446
medicine & public health (1388) 1388
retrospective studies (1378) 1378
apixaban (1366) 1366
dentistry (1258) 1258
oral anticoagulant-therapy (1204) 1204
safety (1196) 1196
warfarin - adverse effects (1190) 1190
adolescent (1189) 1189
bleeding (1169) 1169
dose-response relationship, drug (1168) 1168
abridged index medicus (1159) 1159
thromboembolism - prevention & control (1157) 1157
risk assessment (1149) 1149
stroke prevention (1143) 1143
health aspects (1131) 1131
drug therapy (1113) 1113
prospective studies (1110) 1110
antithrombotic therapy (1086) 1086
direct oral anticoagulants (1070) 1070
aspirin (1056) 1056
deep-vein thrombosis (1056) 1056
patients (1038) 1038
blood coagulation - drug effects (1037) 1037
follow-up studies (1030) 1030
vitamin k - antagonists & inhibitors (1020) 1020
pharmacokinetics (1010) 1010
stroke - etiology (1000) 1000
research (984) 984
mortality (969) 969
hemorrhage (959) 959
molecular-weight heparin (932) 932
internal medicine (922) 922
rats (914) 914
cardiology (874) 874
anticoagulants - pharmacology (868) 868
risk-factors (853) 853
prothrombin time (848) 848
young adult (843) 843
dosage and administration (835) 835
drug interactions (830) 830
metaanalysis (830) 830
cardiac arrhythmia (808) 808
efficacy (804) 804
thrombin (796) 796
drug administration schedule (793) 793
clinical trials (743) 743
venous thrombosis (736) 736
oral contraceptives (709) 709
medical research (695) 695
pregnancy (689) 689
incidence (669) 669
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
UTL at Downsview - May be requested (145) 145
Dentistry (Harry R Abbott) - Stacks (83) 83
Dentistry (Harry R Abbott) - Withdrawn (52) 52
Gerstein Science - Stacks (52) 52
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (51) 51
Collection Dvlpm't (Acquisitions) - Closed Orders (9) 9
Dentistry (Harry R Abbott) - Circulation Desk (7) 7
Online Resources - Online (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
Dentistry (Harry R Abbott) - May be requested (6) 6
Dentistry (Harry R Abbott) - Searching (3) 3
Lakeridge Health Sciences - Oshawa (3) 3
Robarts - Stacks (3) 3
Scarborough Hospital - Birchmount (2) 2
St. Michael's Hospital - Stacks (2) 2
UofT at Mississauga - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Dentistry (Harry R Abbott) - Course Reserves (1) 1
Dentistry (Harry R Abbott) - Mending (1) 1
Dentistry (Harry R Abbott) - Missing (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Regis College - Stacks (1) 1
Royal Ontario Museum - Reference (1) 1
Scarborough Hospital - General (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UTL at Downsview - Withdrawn (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (20432) 20432
German (682) 682
French (422) 422
Spanish (409) 409
Italian (165) 165
Russian (138) 138
Japanese (93) 93
Portuguese (87) 87
Polish (72) 72
Hungarian (44) 44
Czech (21) 21
Turkish (21) 21
Danish (20) 20
Dutch (18) 18
Norwegian (15) 15
Chinese (14) 14
Swedish (14) 14
Korean (12) 12
Arabic (8) 8
Hebrew (8) 8
Bulgarian (6) 6
Finnish (6) 6
Serbian (6) 6
Slovenian (5) 5
Croatian (4) 4
Romanian (4) 4
Lithuanian (2) 2
Bosnian (1) 1
Estonian (1) 1
Georgian (1) 1
Icelandic (1) 1
Persian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 2012, Volume 59, Issue 16, pp. 1413 - 1425
Journal Article
American Heart Journal, ISSN 0002-8703, 2016, Volume 182, pp. 28 - 35
Background Non-vitamin K antagonist oral anticoagulants (NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban) have been increasingly used as alternatives to... 
Cardiovascular | INTRAVENOUS THROMBOLYSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | DABIGATRAN ANTICOAGULATION | TISSUE-PLASMINOGEN ACTIVATOR | WARFARIN | ACUTE ISCHEMIC-STROKE | GUIDELINES | INTRACEREBRAL HEMORRHAGE | RISK SCORE | HEALTH-CARE PROFESSIONALS | INTRACRANIAL HEMORRHAGE | United States - epidemiology | Dabigatran - adverse effects | Dabigatran - administration & dosage | Anticoagulants - administration & dosage | Humans | Stroke - diagnosis | Warfarin - adverse effects | Male | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Medication Therapy Management - standards | Warfarin - administration & dosage | Rivaroxaban - administration & dosage | Thiazoles - adverse effects | Pyridones - administration & dosage | Pyridines - adverse effects | Rivaroxaban - adverse effects | Adult | Female | Registries | Stroke - therapy | Pyrazoles - adverse effects | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Emergency Treatment - methods | Anticoagulants - adverse effects | Outcome and Process Assessment (Health Care) | Pyrazoles - administration & dosage | Stroke - etiology | Quality Improvement | Antithrombins - adverse effects | Emergency Treatment - mortality | Pyridones - adverse effects | Cohort Studies | Stroke (Disease) | Warfarin | Diet therapy | Stroke patients | Atrial fibrillation
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2014, Volume 64, Issue 11, pp. 1128 - 1139
Abstract Background Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | monitoring | laboratory | apixaban | MEASURING RIVAROXABAN | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | DABIGATRAN CONCENTRATIONS | PROTHROMBIN TIME | PARTIAL THROMBOPLASTIN TIME | COAGULATION ASSAYS | IN-VITRO | FACTOR-XA INHIBITOR | PLASMA-CONCENTRATIONS | INTERNATIONAL NORMALIZED RATIO | Anticoagulants - administration & dosage | Humans | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Factor Xa Inhibitors - administration & dosage | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - pharmacology | Factor Xa Inhibitors - pharmacology | beta-Alanine - analogs & derivatives | Pyrazoles - pharmacology | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Pyrazoles - administration & dosage | Partial Thromboplastin Time | Anticoagulants - pharmacology | Benzimidazoles - pharmacology | Drug Monitoring | Pyridones - pharmacology | Measurement | Anticoagulants (Medicine) | Vitamins | Studies | Anticoagulants | Plasma | Bibliographic literature | Laboratories | Drug therapy | Drug dosages | Bone surgery
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e44S - e88S
Background: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant... 
GAMMA-CARBOXYGLUTAMIC ACID | INTRAVENOUS PHYTONADIONE VITAMIN-K-1 | FACTOR-XA INHIBITOR | VENOUS LIMB GANGRENE | EUROPEAN CONCERTED ACTION | LOW-INTENSITY WARFARIN | RESPIRATORY SYSTEM | VITAMIN-K ANTAGONISTS | TOTAL HIP-REPLACEMENT | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | United States | Humans | Pyridines - pharmacokinetics | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacokinetics | Dose-Response Relationship, Drug | Rivaroxaban | Pyridines - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Benzimidazoles - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Morpholines - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Evidence-Based Medicine | Factor Xa - metabolism | Thiophenes - pharmacokinetics | Vitamin K - blood | Antithrombins - adverse effects | Anticoagulants - pharmacokinetics | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2013, Volume 109, Issue 4, pp. 569 - 579
Journal Article
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e152S - e184S
Background: High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This... 
COMPUTERIZED DECISION-SUPPORT | INTENSITY WARFARIN THERAPY | DEFINITE ANTIPHOSPHOLIPID SYNDROME | RESPIRATORY SYSTEM | PROTHROMBIN COMPLEX CONCENTRATE | MOLECULAR-WEIGHT HEPARIN | DEEP-VEIN THROMBOSIS | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | ACUTE VENOUS THROMBOEMBOLISM | ORAL VITAMIN-K | CRITICAL CARE MEDICINE | United States | Humans | Decision Support Systems, Clinical | Heparin - therapeutic use | Hemorrhage - prevention & control | Long-Term Care | Heparin - adverse effects | Heparin - pharmacokinetics | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Drug Interactions | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Drug-Related Side Effects and Adverse Reactions | Fibrinolytic Agents - therapeutic use | Thrombosis - blood | Thrombosis - prevention & control | Patient Education as Topic | Polysaccharides - therapeutic use | Drug Administration Schedule | Administration, Oral | Hemorrhage - therapy | Polysaccharides - adverse effects | Evidence-Based Medicine | Randomized Controlled Trials as Topic | International Normalized Ratio | Thrombosis - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Self Care | Polysaccharides - pharmacokinetics | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2016, Volume 115, Issue 4, pp. 685 - 711
Journal Article
American Heart Journal, ISSN 0002-8703, 2017, Volume 190, pp. 12 - 18
Background Oral anticoagulation prevents ischemic strokes in patients with atrial fibrillation. Early detection of atrial fibrillation and subsequent... 
Cardiovascular | FIBRILLATION | CARDIAC & CARDIOVASCULAR SYSTEMS | STROKE PREVENTION | WARFARIN | CLINICAL-IMPLICATIONS | AMERICAN-COLLEGE | CARDIAC MONITOR | RISK | OPEN-LABEL | TEMPORAL RELATIONSHIP | ISCHEMIC-STROKE | Prospective Studies | Follow-Up Studies | Humans | Male | Thiazoles - administration & dosage | Atrial Fibrillation - physiopathology | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Time Factors | Female | Stroke - epidemiology | Vitamin K | Heart Rate | Stroke - prevention & control | Pyridines - administration & dosage | Survival Rate - trends | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Europe - epidemiology | Treatment Outcome | Disease-Free Survival | Stroke - etiology | Atrial Fibrillation - epidemiology | Aged | Fibrinolytic Agents - administration & dosage | Stroke (Disease) | Care and treatment | Anticoagulants (Medicine) | Stroke patients | Atrial fibrillation | Cardiac patients | Implants, Artificial | Prosthesis | Anticoagulants | Therapy | Cardiac arrhythmia | Surgical implants | Aspirin | Stroke | Coagulation | Strokes | Patients | Bleeding | Risk factors | Vitamins | Artifacts | Fibrillation | Ischemia | Defibrillators | Pacemakers | Safety engineering | Electrocardiography | Heart diseases | Trial Design
Journal Article